BS BSX Boston Scientific Loading... : Bullish and Bearish Analyst Opinions

BSX trades at ~$57 vs Morningstar fair value of $81 and CFRA $67.63; EPS CAGR estimated 11-16% over next 5 years; CEO Mahoney has driven 16% EPS growth since 2010 with 85% accuracy. Valuation gap (discount to fair value) combined with strong product moats (PFA, WATCHMAN) and a proven management turnaround creates a buying opportunity. BSX is undervalued relative to its historical and projected earnings power, with catalysts from new product cycles and a long-tenured CEO. Competition from JNJ and Medtronic eroding PFA market share (projected drop from 58% to 48% by 2026); execution hiccups and recent guidance down; sector becoming capex-heavy and binary.

SEC FOIA logs reveal ongoing investigations for listed companies, indicating regulatory scrutiny but no directional view expressed.

Bearish view on BSX expecting stock decline on CEO retirement catalyst in ~2 years; recent overearning will revert, and sour investor sentiment compounds downside.

Bearish view on BSX as CEO's $15M insider sale before a blackout period signals bearish conviction about the company's near-term outlook.

The tweet implies insider selling by BSX's CEO before a blackout period, suggesting bearish sentiment on the stock's near-term outlook.

Bearish view on BSX as the sharp +9% squeeze is unsustainable and signals a negative reversal.

Boston Scientific wait for bottom

Boston Scientific's CHAMPION trial results are viewed as meeting guidelines but failing to provide the significant upside bulls expected.

The author is bullish on Boston Scientific due to strong long-term earnings potential and high trial success probability, despite some short-term concerns regarding Q1 performance.